These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1112 related articles for article (PubMed ID: 19481021)
1. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin. Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021 [TBL] [Abstract][Full Text] [Related]
2. Fluvastatin as co-medication in heart transplant recipients with elevated creatine-kinase. Sadoni S; Kaczmarek I; Delgado O; Schmöckel M; Reichart B; Meiser B Transplant Proc; 2007 Mar; 39(2):558-9. PubMed ID: 17362781 [TBL] [Abstract][Full Text] [Related]
3. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658 [TBL] [Abstract][Full Text] [Related]
4. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. Wissing KM; Unger P; Ghisdal L; Broeders N; Berkenboom G; Carpentier Y; Abramowicz D Transplantation; 2006 Sep; 82(6):771-8. PubMed ID: 17006324 [TBL] [Abstract][Full Text] [Related]
5. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion. White M; Haddad H; Leblanc MH; Giannetti N; Pflugfelder P; Davies R; Isaac D; Burton J; Chan M; Azevedo E; Howlett J; Ignaszewski A; Busque S; Cantarovich M; Ferguson R; Genest J; Ross H J Heart Lung Transplant; 2005 Jul; 24(7):798-809. PubMed ID: 15982605 [TBL] [Abstract][Full Text] [Related]
6. Safety and effects on the lipid and C-reactive protein plasma concentration of the association of ezetimibe plus atorvastatin in renal transplant patients treated by cyclosporine-A: a pilot study. Panichi V; Manca-Rizza G; Paoletti S; Taccola D; Consani C; Sbragia G; Mantuano E; Marchetti V; Carpi A; Barsotti G Biomed Pharmacother; 2006 Jun; 60(5):249-52. PubMed ID: 16740374 [TBL] [Abstract][Full Text] [Related]
7. Impact of fluvastatin on hyperlipidemia after renal transplantation. Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777 [TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation. Demetriou D; Shabpar A; Böhmig G; Schmaldienst S; Hörl WH; Watschinger B Wien Klin Wochenschr; 2000 Apr; 112(8):358-61. PubMed ID: 10849941 [TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation. Crespo-Leiro MG; Paniagua MJ; Marzoa R; Grille Z; Naya C; Flores X; Rodriguez JA; Mosquera V; Franco R; Castro-Beiras A Transplant Proc; 2008 Nov; 40(9):3060-2. PubMed ID: 19010194 [TBL] [Abstract][Full Text] [Related]
10. Ezetimibe in heart transplantation: initial experience. Moro J; Almenar L; Martínez-Dolz L; Izquierdo M; Agüero J; Sánchez-Lazaro I; Ortiz V; Salvador A Transplant Proc; 2007 Sep; 39(7):2389-92. PubMed ID: 17889199 [TBL] [Abstract][Full Text] [Related]
11. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients. Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505 [TBL] [Abstract][Full Text] [Related]
12. Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. Taylor PJ; Kubler PA; Lynch SV; Allen J; Butler M; Pillans PI Ann Pharmacother; 2004 Feb; 38(2):205-8. PubMed ID: 14742751 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation. Aliabadi AZ; Mahr S; Dunkler D; Grömmer M; Zimpfer D; Wolner E; Grimm M; Zuckermann AO Transplantation; 2008 Dec; 86(12):1771-6. PubMed ID: 19104420 [TBL] [Abstract][Full Text] [Related]
14. Supratherapeutic response to ezetimibe administered with cyclosporine. Koshman SL; Lalonde LD; Burton I; Tymchak WJ; Pearson GJ Ann Pharmacother; 2005 Sep; 39(9):1561-5. PubMed ID: 16030077 [TBL] [Abstract][Full Text] [Related]
15. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. Brown AS; Bakker-Arkema RG; Yellen L; Henley RW; Guthrie R; Campbell CF; Koren M; Woo W; McLain R; Black DM J Am Coll Cardiol; 1998 Sep; 32(3):665-72. PubMed ID: 9741509 [TBL] [Abstract][Full Text] [Related]
17. Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects. Puccetti L; Bruni F; Bova G; Cercignani M; Palazzuoli A; Console E; Auteri A; Pasqui AL Nutr Metab Cardiovasc Dis; 2001 Dec; 11(6):378-87. PubMed ID: 12055702 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Vanhaecke J; Van Cleemput J; Van Lierde J; Daenen W; De Geest H Transplantation; 1994 Jul; 58(1):42-5. PubMed ID: 8036706 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of atorvastatin in heart transplant recipients. Patel DN; Pagani FD; Koelling TM; Dyke DB; Baliga RR; Cody RJ; Lake KD; Aaronson KD J Heart Lung Transplant; 2002 Feb; 21(2):204-10. PubMed ID: 11834348 [TBL] [Abstract][Full Text] [Related]
20. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study. Farsang C; Athyros V; Gaw A; Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]